ClinicalTrials.gg
CompletedNCT01569113Updated Jun 13, 2013

Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® or Placebo.

A Phase 4 interventional study of Ulipristal Acetate (UPA) + ethinylestradiol/levonorgestrel (Microgynon) and placebo + ethinylestradiol/levonorgestrel in Emergency Contraception, sponsored by HRA Pharma. Completed at 3 sites in 3 countries. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-06-13.

Sponsored by HRA Pharma · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

The purposes of this study are to compare the effects on ovarian activity of quick starting a Combined Oral Contraceptive Pill (COCP) after ellaOne® or placebo intake.

02

Conditions studied

  • Emergency Contraception

Keywords

  • ella
  • ellaOne
  • quickstart
  • contraception
  • combined oral pill
  • microgynon
03

In context

Lead sponsor

HRA Pharma is the lead sponsor of 14 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Healthy women aged 18-35 years old
  • \< 30 Kg/m2
  • Not at risk of pregnancy
  • No use of progesterone-only-pill for 3 months before start of treatment cycle
  • No use of implant hormonal for 3 months before start of treatment cycle
  • No use of levonorgestrel intrauterine system for 3 months before start of treatment cycle
  • No use of depo provera for 12 months before start of treatment cycle
  • Able to give .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    ellaOne + microgynon 30

    Drug: Ulipristal Acetate (UPA) + ethinylestradiol/levonorgestrel (Microgynon)

  • Placebo comparator
    placebo + microgynon 30

    Drug: placebo + ethinylestradiol/levonorgestrel

Interventions

  • DrugUlipristal Acetate (UPA) + ethinylestradiol/levonorgestrel (Microgynon)

    UPA: 30 mg, 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake

    Also known as: ellaOne + Microgynon 30

  • Drugplacebo + ethinylestradiol/levonorgestrel

    placebo: 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake

    Also known as: Microgynon 30

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with a Hoogland score consistent with ovarian quiescence (≤3) after 1 to 21 days of intake of COCP in both groups (preceded by the intake of ellaOne® or placebo).

    Time frame: Day 1 to day 21 of intake of microgynon 30

Secondary outcomes

  1. Number of days of intake of COCP required to reach ovarian quiescence (Hoogland score ≤3) after the intake of ellaOne® or placebo.

    Time frame: Day 1 to day 21 of intake of microgynon 30

07

Study locations

3 sites
  • Dinox
    Groningen, 9713, Netherlands
  • Karolinska University Hospital Solna
    Stockholm, SE-171 76, Sweden
  • Chalmers Sexual Health Clinic
    Edinburgh, Scotland EH3 9ES, United Kingdom
08

References and documents

Publications

  • Cameron ST, Berger C, Michie L, Klipping C, Gemzell-Danielsson K. The effects on ovarian activity of ulipristal acetate when 'quickstarting' a combined oral contraceptive pill: a prospective, randomized, double-blind parallel-arm, placebo-controlled study. Hum Reprod. 2015 Jul;30(7):1566-72. doi: 10.1093/humrep/dev115. Epub 2015 May 20. PubMed 25994664 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2012
First posted
Apr 2, 2012
Start
Mar 2012
Primary completionActual
Aug 2012
CompletionActual
Aug 2012
Last update
Jun 13, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01569113
Lead sponsor
HRA Pharma
Responsible party
Sponsor
First posted
Apr 2, 2012
Start date
Mar 2012
Primary completion
Aug 2012
Completion
Aug 2012
Last update
Jun 13, 2013

Study contacts

Sharon Cameron, MD
principal investigator · Chalmers Sexual Health Clinic

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion